The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography and magnetic resonance imaging (MRI) was evaluated. Thus, 29 BRCA-MCs with breast cancer were retrospectively evaluated and the results compared with an age, tumor size and tumor type matched control group of 29 sporadic breast cancer cases. Detection rates on both modalities were evaluated. Tumors were analyzed on morphology, density (mammography), enhancement pattern and kinetics (MRI). Overall detection was significantly better with MRI than with mammography (55/58 vs 44/57, P=0.021). On mammography, lesions in the BRCA-MC group were significantly more described as rounded (12//19 vs 3/13, P=0.036) and with sharp margins (9/19 vs 1/13, P=0....
BACKGROUND: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
Item does not contain fulltextThe appearance of malignant lesions in BRCA1 and BRCA2 mutation carrie...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
Our review of the images from prior MR imaging examinations shows that the cancers grow in size and ...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
BACKGROUND: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
Item does not contain fulltextThe appearance of malignant lesions in BRCA1 and BRCA2 mutation carrie...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography a...
Our review of the images from prior MR imaging examinations shows that the cancers grow in size and ...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
BACKGROUND: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...
Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using M...